Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure. In considering outcomes for ...

The FDA recently approved a pretzel-shaped implant that helps some bladder cancer patients keep their bladder. Dr. Chris ...

Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common ...

The findings showed that disease progression not only worsens patient outcomes but also significantly increases overall healthcare costs. Late-stage disease and post-recurrence cystectomy were ...

Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Q3 2025 Earnings Call Transcript November 13, 2025 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM ESTCompany ParticipantsSteve Chapman - CEO & ...

In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...

Aura Biosciences advances bel-sar in eye cancers with promising signals, facing potential cash needs before the Phase 3 ...

Men’s health is an often-overlooked topic, even though it affects not only individual wellbeing but also families and ...

Artificial intelligence (AI) is set to transform the care of women with cancer. From early detection via digital phenotyping ...